Interactive Transcript
0:02
Hello, and welcome to Noon Conference hosted by Modality.
0:05
Noon Conference connects the global radiology community through free live
0:09
educational webinars that are accessible for all and is an opportunity to learn
0:12
alongside top radiologists from around the world.
0:16
Today, we are honored to welcome Dr.
0:17
Justin Stoll for a lecture entitled "Imaging Considerations After
0:20
Gender-Affirming Therapies." Dr.
0:22
Stoll completed his residency at the University of Missouri, Kansas City, and a
0:26
thoracic imaging fellowship at Massachusetts General Hospital, Harvard Medical
0:30
School.
0:31
Since joining the Mayo Clinic in 2019, he has served as lead radiologist for the
0:35
Florida Lung Cancer Screening Program.
0:38
His clinical interests include interstitial lung disease, lung cancer screening and
0:41
therapeutics, and developmental lung disease.
0:44
He also advocates for and educates about the healthcare needs of the transgender
0:48
community, especially in the field of radiology.
0:51
At the end of the lecture, please join him in a Q&A session where he will address
0:54
questions you may have on today's topic.
0:56
Please remember to use the Q&A feature to submit your questions so we can get to as
1:00
many as we can before our time is up.
1:02
With that, we're ready to begin today's lecture. Dr.
1:04
Stoll, please take it from here.
1:07
All right. We'll go ahead and get started.
1:11
So
1:12
this discussion is about imaging considerations for transgender patients,
1:16
which are a unique population that we care for in radiology.
1:21
So today I want to just emphasize basically all the things that we should be
1:24
considering from an imaging perspective in caring for these patients.
1:29
Okay, so I have no relevant disclosures to this talk other
1:33
than-- But I do want to say that I am cisgender, meaning that my gender identity
1:37
aligns with the sex that was assigned to me at birth.
1:40
And so
1:41
during this talk, I'll discuss transgender patients'
1:44
experiences in the radiology encounter, and I want to
1:49
just emphasize that it's through the lens of a cisgender individual and from what
1:53
I've heard from the community, from patients' feedback, also what
1:57
I've studied from the literature, and then also what I've heard among the
2:00
community, for example. So I want to just disclose that this is
2:04
potentially a slight bias through a cisgender lens, but I'll
2:08
try to be as objective moving forward with that and emphasize the community
2:12
aspect of this.
2:16
So first I'll do some introduction with terminology and epidemiology and
2:20
care standards. We actually have care standards for transgender health, kind
2:24
of dominated and
2:27
organized by the World Professional Association for Transgender Health, or
2:31
WPATH.
2:32
And so I consider them the WHO for transgender
2:36
healthcare. It's a great organization that
2:39
really looks at the data and the standards and
2:42
tries to make it--
2:45
or has developed standards of care.
2:47
And then I'll really emphasize the new anatomy related to gender surgery,
2:52
and how the imaging can be used in the diagnosis and management of any
2:55
complications of that.
2:57
Also, same thing with hormones and potential changes of hormone therapies and how
3:00
that might affect our imaging. And then finally, I'll end the talk with discussions
3:04
about how we can make our departments more affirming and welcoming for these
3:08
patients, whether it's processes and procedures, or at least just start the
3:11
discussion of ways that we might be able to improve the encounter.
3:15
So as an introduction and getting everyone on the same page,
3:19
the gender identity-- So we're talking about gender identities today when we speak
3:22
of transgender patients. And a transgender person has a gender
3:26
identity or their inner sense or experience of gender that
3:30
differs from the sex that was assigned to them at birth, which
3:34
is usually based on external genitalia.
3:38
And not often is a chromosomal analysis even conducted, or maybe there's some
3:42
prenatal ultrasound that's mainly focused on external genitalia.
3:45
However,
3:47
the body or the sex organs develop at a
3:51
different time than our gender identity, and it's understood that gender identity
3:55
is more of an inner experience, and it probably develops more close to around
3:59
the age of three, maybe four, where people start to recognize, I'm
4:03
a boy or she's a girl, for example. And so there's a
4:06
discordance with when we develop physically and when we
4:10
develop intellectually and internally.
4:14
A trans man, for the purpose of this discussion, will be
4:18
someone whose gender identity is male or
4:21
masculine and was assigned female sex at birth.
4:25
Vice versa for trans woman, someone who was assigned male sex at birth but
4:28
identifies as feminine or a woman.
4:32
Gender diverse is kind of an inclusive category for folks that don't
4:36
identify on a binary spectrum. So they may be somewhere in between, neither,
4:40
or both. I'll use the term trans masculine, trans feminine to
4:45
honor that spectrum of gender identity,
4:48
rather than being completely binary.
4:50
And then gender dysphoria is the actual diagnostic
4:54
term from the DSM-5 related to psychological or social
4:58
distress caused by this gender incongruence with
5:02
the sex assigned at birth and gender identity.
5:05
I want to emphasize that transgender and gender identity
5:09
are not diagnoses. They're not something we treat. We don't treat transgender.
5:13
We treat gender dysphoria because of this incongruence and how
5:18
it's affecting the patient. And so we have different treatments, which I'll
5:21
discuss, that we can apply to help alleviate gender dysphoria.
5:25
Sexual orientation is completely different than gender identity, but it's often
5:29
included among that LGBTQ rainbow, kind of that
5:33
umbrella. But sexual orientation is one's individual preference or
5:37
desire for sexual intimacy with others, whether it's a cisgender person
5:41
or a transgender person. So
5:43
sexual orientation can be anything among the transgender community.
5:47
And then, as I mentioned, the gender-affirming therapies, whether it's
5:50
psychological, social transition, hormones, or potentially surgery.
5:55
Those gender-affirming therapies are listed here.
5:57
We have feminizing gender-affirming therapies and masculinizing therapies.
6:01
Not all patients will require all of these to feel affirmed in
6:05
their selves. And so
6:07
Just understand that not every person, just because they identify as transgender,
6:10
may require the full spectrum of all these treatments.
6:13
Some may only need a social transition or psychological support,
6:18
and may not even require hormones or surgery.
6:21
So that's something I wanted to emphasize here, but
6:25
these are the options that are available for these patients.
6:29
There was a large survey done in the United States that was published in
6:33
2015, and this was over 50,000 respondents.
6:36
But this is just showing you that the desire for these various gender-affirming
6:40
therapies can be highly variable, and you can see that
6:44
some things are highly desired. A lot of patients have it or want it
6:48
someday.
6:50
For example, some of the more advanced surgical options, a lot of patients don't
6:54
desire those or may not necessarily desire those.
6:58
This is data from
7:01
US insurance claims, and we did have an expanding
7:05
health insurance coverage for transgender care.
7:08
There was an increase in demand of gender-affirming care in the United States.
7:11
But despite all this, there's still high rates of healthcare avoidance among this
7:15
population, and this is just data from this study that looked at US
7:19
claims up to 2020, and it shows that there was an overall
7:23
increase in demand in utilization of gender-affirming surgeries.
7:27
And you can see how that's broken down, whether it's breast or chest surgery versus
7:30
a genital surgery or some other cosmetic surgery there.
7:34
And if you look at the age category of the patients that are undergoing surgery,
7:37
you can see that often a breast or a chest surgery is the earliest type of
7:41
surgery they might pursue, followed by the genital surgeries are usually at
7:45
a later age. And that's probably related to when breast tissue starts
7:49
to develop, for example, in a transmasculine person, they may desire to have
7:53
top surgery to remove that, as that's the part that's causing them so much
7:57
dysphoria. And so that may be applied earlier,
8:01
or it's just easier to access some of those types of surgeries, or maybe that's all
8:04
they require, so they start early, and that's all they need,
8:07
and then some of the other surgeries come later.
8:10
So epidemiologically speaking, I like to get a snapshot of where are the
8:14
patients and how many patients are we talking about.
8:16
And so there's not a
8:19
real good, robust collection of this type of
8:23
data. There is no question on the US
8:27
Census to collect this data, but we do have some large surveys that were conducted
8:30
in the United States. So you can see that worldwide, it's estimated about 25
8:34
million trans persons are across the globe.
8:37
Probably an underestimation, to be honest.
8:40
In the US, it's estimated at about 0.8% of US adults,
8:43
or if you do the numbers, about 2 million.
8:46
And you can see how that's broken down by gender identity here.
8:49
Youth comprise about an estimation of 3.3% of youth in the
8:52
United States. And you can see from this map
8:56
where those patients reside or where those people are residing.
8:58
And so I was surprised to see the distribution that the highest
9:02
concentration is in
9:04
some of the highest concentrations in the South.
9:07
Here's an
9:09
update of the Transgender Health Survey that was published in 2022, again,
9:13
over 92,000 respondents, again, showing that we have trans
9:17
patients living all across the United States in
9:21
outlying territories, and again, the highest concentration in the South.
9:26
Canada does include this data point on their census, and so this is
9:30
Canadian census data showing the relative breakdown of
9:33
transgender folks in that
9:36
population in Canada.
9:38
And then other countries that collect this data, again, Belgium, New
9:41
Zealand. The image on the right is data from
9:45
one transgender health clinic in the Netherlands that's been serving as a
9:49
central core clinic for transgender health for many years,
9:53
and you can see the increasing demand,
9:56
especially among adults and even youth and adolescents.
9:59
So we see growing number of people that have been
10:03
identifying as transgender and coming to care.
10:08
So these gender-affirming therapies, what are the effects of them and what are the
10:11
outcomes? And so across many, many publications, we see
10:15
continued results showing that patients who are given access to
10:19
hormones or surgery for gender-affirming therapies result in a much more
10:22
satisfied life, and are much more satisfied with
10:26
themselves. Very few express regret or undergo regret.
10:30
And so you can see that from these data, again, this comes back over and over again
10:34
in the literature. So it shows that gender-affirming therapies are
10:38
evidence-based and effective.
10:41
I include this slide only because I think it's important for radiologists to know
10:44
that these patients do, unfortunately, as a population, suffer from
10:48
higher rates of violence inflicted upon them, and you can see how that's broken
10:52
down here. And so unfortunately, this population may be subject to
10:56
violence, and that might be reflected in some of the things we see on our imaging.
10:59
So keep that in mind that you might see non-accidental trauma in the
11:03
adult, for example, in some of these patients.
11:05
So keep a lookout when you're imaging these patients.
11:09
This is just data that shows around 65% across a
11:12
meta-analysis of the literature shows that a rate of around
11:16
65% have expressed some form of violence.
11:21
So how does radiology fit into all this?
11:23
So we know that medical imaging is prolific.
11:25
It's used by almost every other subspecialty department.
11:28
So transgender patients are no different in that they will probably encounter
11:32
imaging or have an imaging encounter at some point through their journey in
11:36
healthcare. And again, that can be from general medical conditions, coming in for
11:40
anything. Here's an example of appendicitis in a trans woman who had undergone
11:43
vaginoplasty.
11:45
Or they could be coming specifically to evaluate
11:48
problems related or physiological effects of their
11:52
gender-affirming therapy. So nonetheless, radiology is central to this care, and so
11:55
that's why we're here today to discuss it.
11:58
So I got interested in this study, and I wanted to really focus on
12:03
how does the transgender patient have a
12:07
radiology encounter, and what are the steps, the touch points that they might
12:11
have access to, and how do we interact with them?
12:14
And so I did a large survey back in 2020 already,
12:18
believe it or not, or before that. And so it was published in 2020, but
12:22
this is some data. So I'll present some of that data from that survey, just so you
12:25
have an idea of how these patients encounter our department specifically.
12:28
It includes data from over 500 respondents
12:32
across the United States, so pretty robust collection of patients and their
12:36
experiences in radiology.
12:38
So what we found was 71% had at least one negative experience when
12:42
coming to radiology departments, and half felt that their gender identity was the
12:46
reason for that discomfort in the department.
12:49
A quarter experienced negative interactions with imaging staff.
12:52
And so,
12:54
patient-facing individuals might have been the reason for these negative
12:57
encounters. A third had to instruct the staff about transgender people to
13:01
receive appropriate care. That is the same as for a
13:05
large
13:06
primary care survey that was done, a separate one.
13:10
So about a third had to
13:12
explain what transgender people were to the providers to get
13:16
care. And then within radiology, again, about a third said that
13:19
the staff seemed uncomfortable caring for them.
13:21
And so, those are things that we could work on.
13:24
So that all speaks to me as education of our providers, and so again, why we're
13:28
here. These are quotes from folks who participated in our
13:32
survey. I wanted the voice of the trans patient to come through so we can
13:36
really get a granular understanding of what's happening.
13:38
So I'll let you just read those thought bubbles, but those are actual quotes.
13:41
But you can see that again,
13:44
this data point was 16.7% were made to feel unwelcome or
13:47
unsafe. And, I think that's unacceptable for any of our patients, whether you're
13:51
trans or cisgender. I think that should be a 0% for anyone.
13:55
And so there's some work we can do in radiology.
14:00
I wanted to know, were these encounters through the emergency department,
14:03
outpatient, inpatient? Maybe the emergency department is a stressful
14:07
setting anyway, and maybe that had a heightened
14:11
negative encounter. But actually, most of the respondents had had outpatient
14:15
imaging encounters, so relatively calm, cool, controlled
14:18
environments. And unfortunately, they were still having these experiences.
14:22
There was really no association with the population or where
14:26
the patient was located, whether it was urban, suburban, or rural imaging
14:30
departments,
14:31
whether they had a positive or negative experience.
14:33
So it told me across the board, radiology has some work to do to improve.
14:38
So I'm going to do this a little different than the last time that I presented for
14:42
Mediality and MRI online. I'm going to do a case-based approach so that it
14:46
really shows you and highlights the patient experience.
14:49
These are real patient cases that I've anonymized, but these are ones that
14:53
actual trans patients in their encounters in radiology.
14:56
So first, we'll start with Jack. He's a transgender man, meaning he was assigned
14:59
female sex at birth, identifies as a man, is sitting in the waiting room for a
15:03
breast imaging center. The staff from the front desk calls out
15:06
Jessica, which is Jack's legal name, that's on his documentation still,
15:10
and he responds embarrassingly and walks up to the front desk.
15:14
And again, his expressed gender for all the other people in the waiting room is
15:18
very different than you would expect someone named Jessica.
15:21
So Jack, other patients in the waiting room, the staff person,
15:24
created an uncomfortable scenario.
15:28
And for Jack, immediately, this breast imaging center is not a safe
15:32
space, right? The limelight's on him.
15:35
So with regards to those terms, that's why terminology is so much
15:38
emphasized among this population and among education here, is that when we
15:42
misgender someone or refer to the wrong gender or
15:46
pronoun, for example,
15:48
that can really affect these patients.
15:51
And it's an exposure, it creates an unsafe space for them.
15:55
And it's inaccurate. So it's something that we should be more accurate about
15:58
because these are important things as we encounter folks.
16:02
Using a dead name, which is what occurred in this scenario, is the patient's name
16:06
that they no longer
16:09
identify with. Unfortunately, not everyone can undergo legal name changes or
16:13
hasn't
16:14
done that step yet, so it might be different on our medical documentation.
16:17
You just have to be aware of that and sensitive to that.
16:21
Again, I mentioned pronouns and using the right pronouns.
16:24
And, this is sometimes difficult
16:27
for a provider to use the appropriate pronoun, but if you
16:31
mix up, if you use the wrong one, if you misgender, it's not a failure
16:35
on your part. Just quickly apologize, acknowledge the error, and move
16:39
on. And that's actually been shown,
16:41
numerous studies have suggested that that's the best way to do this.
16:44
Don't belabor the mistake. Just be sincere and say, "Oh my gosh,
16:48
I used the wrong pronoun. My apologies, I'll do better.
16:51
And let me know if I make a mistake."
16:54
Ways that we can inform ourselves.
16:56
The EMRs are now available. Patients can
17:00
self-report their gender identity.
17:02
And so look for that sort of thing, or look for other clues, for example,
17:06
including pronouns in name tags and in
17:10
signature lines.
17:12
Another way is just, "How would you like to be addressed today?" Or, "How can I
17:15
best address you?" That's one way to get people, maybe the patient, to just
17:19
disclose that.
17:20
Again, EMRs have this availability, so if your site has that, make sure
17:24
that it's
17:26
available to patients.
17:28
And in our survey, we showed that 25% noted that of
17:32
those discriminatory or non-affirming interactions with radiology
17:36
staff, pronoun use was a highly cited reason for that.
17:38
So again, all part of the education we're providing here, and you can see how
17:42
that played out in our survey. I wanted to know in the
17:46
radiology report, so many patients are reading their reports now.
17:49
How
17:50
often are people misgendered in their reports?
17:52
And one quarter specifically said in the radiology report, they were misgendered.
17:56
So when you're providing a history, you may not even need to
18:00
include the gender. Just say 74-year-old with chest pain, for
18:04
example.
18:06
All right. So other ways, as providers, you can use these pronoun pins.
18:10
My institution allows us to do branded
18:14
pronoun pins if you want to wear them, and it's just a subtle indicator to the
18:18
patient that you may be someone they can open up to, and that
18:22
you maybe are affirming for them in this encounter.
18:25
All sorts of different ways you can do that in a subtle, quiet way without having
18:29
to just ask all the time. All right, next case.
18:33
Robert, a trans man with family history of breast cancer, had top surgery or
18:36
removal of breast tissue to become kind of more masculinized
18:40
chest
18:41
in the last decade. He was counseled on his need for breast cancer screening.
18:45
He did not feel comfortable about the concept of mammograms, and actually was
18:48
dysphoric, but he did agree to go and have a chest wall exam and an
18:52
ultrasound to begin.
18:54
So he was sent to the breast imaging center with an order that specifically said no
18:57
mammogram.
18:59
When he arrives, these are the things that all of our patients are seeing, and this
19:03
came back in our survey. So, they're looking at the signage.
19:06
They're trying to determine, "Is this a safe space for me to be and receive care?"
19:10
And so especially breast imaging centers, they can be heavily gendered, and
19:14
so I would encourage you to look through your breast imaging centers, all of your
19:17
facilities, to see are there subtle signs?
19:20
Are there signs out there, or is it heavily gendered unnecessarily?
19:23
For example, in this case, women's breast imaging area specifically
19:27
was advertising toward women, but we know that all sorts of people use breast
19:31
imaging, including cisgender men.
19:32
And so, that's just one small thing that we can do to really improve
19:36
outcomes for these patients.
19:39
And here's one that the mammogram room was pink and specifically said women
19:42
only, which is kind of interesting if you think of it even in the terms
19:46
of a cisgender man.
19:49
So chest masculinization surgery, which this patient had undergone, is removal
19:53
of breast tissue to create a more masculinized appearance of the chest.
19:57
It is different than oncologic mastectomy, and I think that's important for the
20:00
radiologist to know in that they do often a double incision,
20:05
modified mastectomy, where they remove the inframammary fold.
20:07
That's why you have these transverse incision lines.
20:10
And then they will do a free nipple graft using areolar tissue.
20:14
So they will position it where the plastic surgeons will position this
20:17
appropriate nipple position.
20:20
Their goal is to create a masculinized pectoral swoop to the chest, right?
20:24
So they
20:25
do leave behind some
20:28
fibroglandular tissue, and so that's important and has implications for breast
20:31
cancer risk and
20:33
all of that moving forward. And so that's something for us to know.
20:36
Here's an example on a CT where they thought that the patient might have had an
20:39
infection after top surgery, but this just was expected postoperative
20:43
inflammation and changes in the tissues within two weeks of the surgery.
20:48
You may see drains on the imaging immediately post-op.
20:51
Again, this is just to prevent hematoma formation or seromas, and so
20:55
some patients may require drains.
20:58
So what are breast cancer screening recommendations?
21:00
Remember, this patient was sent to the imaging facility for this indication,
21:04
and so they agreed with a chest wall exam and ultrasound to begin.
21:08
But we used to have varying recommendations for this
21:12
several years ago, and there were different centers of excellence that had the
21:15
recommendations. Mostly similar, but can be different.
21:18
But the American College of Radiology actually came together and
21:22
published in 2021 guidelines for this that are the most comprehensive,
21:26
most evidence-based, and so this is what I would refer you to
21:29
for your transgender breast cancer screening recommendations.
21:34
And for trans men who have had top surgery, we don't have enough data
21:38
to support or advocate for breast cancer screening, so it's
21:42
kind of a gray box. We really don't know the best way to image these patients.
21:45
We also don't know, are these patients willing to come for breast cancer
21:49
screening, right? Either before or after top surgery.
21:52
And in my experience in communicating with the trans community, most are
21:56
not. So we don't have good data to support for or against breast cancer
21:59
screening in this setting.
22:01
What our survey did show is that certain imaging exams can
22:05
produce discomfort for these patients, and so we should be more
22:08
sensitive to the trans community who might have to undergo certain exams.
22:12
One of which, and you can see emotional, psychological, and physical
22:16
discomfort that we collected. And when we asked the question in the survey, we
22:20
said, "This is physical or emotional psychological discomfort that is above and
22:23
beyond that which you would expect or were forewarned
22:27
prior to undergoing the procedure." Not surprisingly, the
22:31
hands-on imaging modalities like image and guided procedures,
22:35
ultrasounds, and mammograms, produced the most physical
22:38
discomfort.
22:40
Similarly, emotional psychological discomfort on the other graph.
22:44
And so if you think about this patient going in for-- They said no mammogram, but
22:48
he was going to do an ultrasound.
22:50
You might provide some
22:54
guidance ahead of time to let them know, "Hey, this could potentially be physically
22:58
or emotionally traumatizing." What worries me is the emotional
23:02
psychological graph. You'll notice the Y-axis is completely different than the
23:06
physical graph. So across all modalities, the patients in our survey were
23:09
reporting higher levels of emotional psychological discomfort
23:13
than that was expected or forewarned for these procedures.
23:17
And then these hands-off modalities shot up.
23:20
About one in five patients reported emotional psychological trauma from
23:23
hands-off sort of imaging modalities.
23:25
So keep that in mind when patients are coming to your center and provide
23:29
anticipatory guidance. I think a lot of these, like the MRI,
23:33
X-ray, CT, might have been based on the feedback, the verbal feedback that we got
23:36
in the survey was from things the patient was hearing while the exam was going on
23:40
from technologists, et cetera. So,
23:43
keep that in mind.
23:45
Here are two examples of mammograms in patients who have had top surgery, and so
23:48
you can see how difficult it is to perform these.
23:50
And so that's why it's probably not the best modality for breast
23:55
cancer screening in this patient population, because one, the patients probably
23:58
don't want to undergo it. Two, it's probably very difficult to achieve a
24:01
high-quality imaging exam. And you can see on the right here, there's a breast
24:05
cancer off screen And so the patient was having a palpable abnormality,
24:09
but you can barely see that breast cancer in this case.
24:12
So what is the risk of breast cancer in trans men?
24:15
We have many case reports. We don't have a comprehensive analysis
24:19
of this. There's one population-based data set coming out of that clinic
24:23
in the Netherlands, which I'll present here.
24:25
But we do know that on average, trans guys who develop
24:29
breast cancer or have the diagnosis, the median age is 41, which is
24:32
younger than expected for most cisgender women.
24:37
Most present in the setting of a diagnostic abnormality rather than a screening,
24:41
and six
24:43
that we know of
24:45
are after chest masculinization or potentially incidental cancers found on
24:49
mastectomy specimen after top surgery.
24:52
So here's just an example of one unfortunate patient who developed a breast cancer
24:56
right along his top surgery incision.
24:59
From that Netherlands cohort that I discussed, they did find that trans men do have
25:03
a higher risk compared to cis men, which would make sense, especially if
25:07
they had not undergone top surgery.
25:10
But they do, especially after top surgery, have a decreased risk compared to
25:13
cisgender women. And again, this is not a risk-reduction mastectomy.
25:17
This is a gender-affirming mastectomy, so there is
25:21
tissue left behind, and there may still be some risk there.
25:25
So let's continue with Robert. He went back to his primary care distressed and said
25:29
he was forced to undergo a mammogram at that visit.
25:31
Now he refuses to have any kind of screening.
25:34
So we just lost a patient because of that encounter.
25:36
So radiology has a significant influence on the care provided to these
25:40
patients, and we should continue to work with our primary care providers and
25:43
referring clinicians to help maximize these experiences for everyone.
25:48
So all these ways we could have done better in this encounter are listed here.
25:51
Again, respect patient autonomy, understand the utility of the imaging.
25:55
Mammography might not have been best for him.
25:58
Again, really seek feedback and provide that anticipatory guidance.
26:03
So next case, Jasmine is a 53-year-old trans woman, feminizing hormones for
26:07
15 years, breast augmentation, vaginoplasty,
26:11
and presented for routine preventative care. She has a mother with breast cancer.
26:14
She's a criminal defense lawyer, history of smoking, and interested in
26:18
pursuing facial feminization. So lots of things to talk about with this
26:22
preventative visit and this patient.
26:25
So again, back to the breast cancer screening.
26:27
We'll jump right to the ACR guidelines because we have that.
26:29
So trans feminine persons at age 40 or older who have
26:33
hormone use greater than five years are considered average risk,
26:37
and so they should undergo annual breast cancer screening.
26:41
And so there's a bit more data behind this, and so we have a pretty strong
26:44
recommendation there.
26:46
And I'll let you guys go ahead and scan this, and this will take you right to the
26:50
ACR recommendations. Again, these are based on expert
26:53
consensus and retrospective cohort studies.
26:55
We don't have prospective data in either trans masculine or trans
26:59
feminine breast cancer screening recommendations.
27:02
I think there are some sites working on this.
27:04
Again, that's going to take a long time to get that data.
27:06
But we do know from many different surveys and different studies that there
27:10
are lower rates of breast cancer screening and adherence among trans
27:14
communities compared to cisgender communities.
27:16
So, some work we need to do to encourage breast cancer
27:20
screening when appropriate.
27:23
So for trans women, we know that breast tissue does develop under
27:27
the influence of feminizing hormones, tends to follow a similar trajectory to
27:31
that of pubertal cisgender women, for example.
27:34
So,
27:35
60% get heterogeneously dense or extremely dense tissue on mammography,
27:39
which we know those are the two independent risk factors for breast cancer.
27:43
Histologically, the tissue is different than, for example,
27:47
gynecomastia. It's actually functional tissue where they develop terminal
27:51
ductal lobule units, and so they can be at risk for the same sort
27:55
of things that cisgender women may be at risk for.
27:58
There are case reports of successful breastfeeding as well, and so again, this is
28:01
functional tissue. Here is an example of histologically proving
28:05
pseudolactational change within a TDLU of a trans
28:09
woman. So I refer to it as feminized breast tissue on my reports
28:13
rather than gynecomastia because it is not the same histologically as
28:16
gynecomastia.
28:18
Here's just active tissue on a bone scan, and again, showing you that this is
28:21
physiologically active tissue. Here's an example of a fiber adenoma
28:25
that was detected, and again, look how dense that tissue is on the
28:29
mammogram. So keep that in mind.
28:32
Breast cancer, what do we know about this?
28:34
So there are 26 reported cases in the literature.
28:37
Average age is 51, again, younger than we would expect for cisgender women.
28:41
And most present, again, outside of the context of screening.
28:45
There were just a few associated with implants.
28:48
And this is one example from our institution where a patient had developed
28:52
progressive swelling of one of the breasts after being on hormone therapy for a few
28:55
years, and it was determined to be a breast cancer.
28:58
She had a genetic predisposition to this that was not known prior
29:02
to starting the hormone therapies.
29:04
And from that cohort in the Netherlands, again, it's a large cohort, so this is the
29:08
best data we have, retrospective.
29:11
There is a 47-fold higher risk among trans women compared to cisgender
29:15
men. And I'm going to pause there just because
29:20
putting that into perspective, cisgender men have a less than
29:23
1%
29:25
chance of developing a breast cancer, very low.
29:28
So 47-fold higher than less than 1% is still pretty low
29:32
overall,
29:33
but side by side, it is higher.
29:36
And then it is three times lower risk compared to cis women.
29:38
So trans women probably fall in between there within the risk
29:42
category. So that's why we have recommendations.
29:46
Some women will elect to undergo augmentation because most don't
29:50
achieve Tanner Stage 5 development, so may undergo silicone or
29:54
saline implants. And so that's important when we come for breast cancer
29:58
screening, that we inform the patients they may need to do implant displaced views.
30:02
You can see in this case, they were able to see the microcalcifications much better
30:05
after doing implant displaced views.
30:08
Silicone injections, injection of free liquid silicone into the
30:12
tissues for augmentation. This is illegal in the United States.
30:16
Unfortunately, this population may be subject to this, whether it's lack of
30:20
access to other types of
30:22
augmentation or that they're actually exploited and targeted in
30:26
social settings, for example, to receive this.
30:28
So it's high risk in that it disfigures the breast, makes it
30:33
very difficult to do
30:35
screening and finding cancers within all that.
30:37
It can
30:38
lead to necrosis and cyst formation, and then it can be taken up in
30:42
the lymphatics and brought to the lungs, for example, and it can be fatal.
30:45
In this case, unfortunately, this trans woman had received silicone injections
30:49
in another country, was flying back to the United States and developed shortness of
30:53
breath and fevers. This was in the pre-COVID era, so
30:57
these were silicone emboli that ultimately led to her demise.
31:00
And you can see the histologic specimens from her lungs showing silicone
31:04
globules within the
31:07
lungs. So continuing with this patient, other forms of preventative care
31:11
we could consider.
31:12
I'm a chest radiologist, so I'm really interested in her smoking history here.
31:16
And so what do we know about cancers in transgender folks?
31:19
So lung cancer is still the most common cancer among all transgender
31:23
folks. So keep that in mind, and that we tend to kind of hone in on
31:27
all these other gender type cancers.
31:28
But lung cancer, unfortunately, is still the highest
31:32
percentage of cancers among this population. You can see the rest broken down here.
31:35
This is based off of US data from the SEER
31:41
database.
31:43
This is UK data, again, showing GI and lung cancers are the
31:47
highest neoplasms that resulted in death in the UK.
31:51
Again, just keep that in mind that lung cancer is prevalent as well as colorectal
31:55
cancer.
31:56
So lung cancer screening, what do we know?
31:58
That this population, although they may be more inclined to smoke than cisgender
32:01
folks for various reasons as listed here, they have these unique
32:05
barriers to getting the preventative screenings that they may need, and that
32:09
includes lung cancer screening. So we did a study where we looked at US
32:12
survey data
32:14
of lung cancer screening utilization and compared transgender versus cisgender,
32:18
and we saw that although the respondents showed a similar
32:22
rate of eligibility, so both cisgender and
32:26
transgender folks in this survey showed similar eligibility rates.
32:30
Of course, utilization was much lower among the transgender community.
32:34
And
32:35
there are various ways that we could think about why that is.
32:38
So
32:39
something to keep in mind.
32:41
Not only just higher rates of tobacco consumption, alcohol use, but also may be at
32:45
risk for certain types of malignancies related to co-infection, like with
32:49
HIV or HPV. So keep those in mind as we're caring
32:53
for this patient population.
32:55
And there is a large study that showed transgender folks are often
32:59
diagnosed at a younger age than cisgender people.
33:02
Their primary site cancers, the rates, the
33:06
proportional incidence rates are higher
33:09
than cisgender people, especially for viral induced cancers.
33:13
So like anal cancer, Kaposi sarcoma, for example, the
33:17
squamous cell type cancers that people can get.
33:21
What is the risk of thromboembolic disease? So this patient is on hormone therapy.
33:25
So we know that there is an increased risk of venous thromboembolism and
33:29
complications related to feminizing hormones,
33:32
especially if
33:34
oral ethinyl estradiol, which is the same as used in birth control, and
33:38
conjugated equine estrogens. Again, these are synthetic estrogens.
33:42
They are not considered the standard of care for gender affirming therapy.
33:45
We use bioequivalent beta estradiol, and that is determined by the
33:49
WPATH organization, that there's more data that shows the risk of
33:52
thromboembolic phenomenon is much lower if you're using the bioequivalent forms,
33:56
and so that's considered the standard of care.
33:59
Supraphysiologic dosing. So these patients on hormone therapy should be getting
34:03
monitored for their estrogen levels.
34:05
And most patients, you know that I think this not when you're
34:09
supraphysiologic, you're going to be higher risk for thromboembolic disease.
34:13
All of the case examples I have are in patients who were very
34:17
supraphysiologic on their dosing, so they weren't getting monitored.
34:20
Again, smoking and some of those other causes.
34:24
This is a large data set from the United States based out of the Kaiser Health
34:27
Institute, again, emphasizing that we do know that there is an increased risk of
34:31
thromboembolic phenomenon or DVT/PE in this
34:35
group, especially the longer someone is on therapy.
34:39
So prostate cancer, again, this is a preventative visit.
34:42
What's this patient's risk for prostate cancer?
34:45
The prostate is not removed during vaginoplasty, which I'll discuss.
34:49
It does atrophy under feminizing hormones, but it's still biologically active.
34:53
Their PSA is not as reliable, but you can trend it.
34:56
It won't meet the same thresholds that a cisgender male
35:00
PSA might before you start getting concerned, but just that's why PSA is
35:04
trended in this population.
35:06
We do know that prostate cancers have been reported.
35:10
It's estimated that the incidence is probably lower than cisgender men,
35:13
mainly because the gland overall is suppressed, but again, it doesn't go to zero.
35:18
And then these patients might not be getting screening, and the reported cases have
35:22
been highly aggressive or highly advanced at the time of the report.
35:26
So still a lot to know about prostate cancer in this population.
35:30
I do have several examples of advanced prostate cancer that's bladder invasive
35:34
within transgender women. You can see it's already
35:36
metastasized to the spine in this case.
35:40
Here's another one with bladder invasive cancer shown on MRI, and then you can see
35:44
early lymph node metastases on the CT.
35:48
So osteoporosis, the effects of hormones on bone health are
35:52
important, and there's quite a bit of data in this.
35:55
And to the point where the ICE, the International Society of Clinical
35:58
Densitometry, has made official position statements because of the amount of data
36:02
available on bone density related to hormone therapy.
36:05
So I would refer you to this table. This is how we should be doing this.
36:08
Your technologist might ask, should we compare to male or female
36:12
nomograms? And this document shares all of those
36:16
information
36:17
Here are just two examples of women who had to come off of their estrogen hormones
36:21
or feminizing hormones for various reasons,
36:24
and they ended up developing osteoporosis, and one developed spinal compression
36:28
fractures from insufficiency.
36:31
Another thing about prevention in this patient is HIV infection and the risks
36:35
that might be present. And so
36:37
trans women have a higher prevalence of HIV infection, and
36:41
we mentioned that in the cancer discussion as well.
36:44
It is a higher incidence compared to cisgender folks, and you can see the breakdown
36:48
also affects different ethnicities, and so that's important to keep in mind
36:53
the rates of HIV infection that might be occurring.
36:55
And whether or not this group is well-controlled in their HIV or maybe not
36:59
getting good control. And again, even in the South, this is a higher
37:03
burden that's been shown by the CDC
37:05
data. If you look at rates of HIV diagnoses, this
37:10
includes cisgender folks, it can be variable.
37:12
So if you're a teleradiologist, where you're reading this patient's case
37:16
from or where this patient resides may affect their-- they may be
37:20
relatively more at risk for these different things based on the state in which they
37:24
live.
37:25
Keep in mind that if someone is uncontrolled with HIV, they may develop
37:28
opportunistic infections, so something to kind of keep in mind while you're reading
37:32
these cases. This is pneumocystis pneumonia in this
37:35
case.
37:37
So facial feminization, the patient's interested in facial feminization.
37:40
So neuroimaging, we are often centered in the middle of
37:44
neuroimaging, or you may just be reading someone's head CT, for example, who has
37:48
undergone facial feminization surgery.
37:50
The goal is to reduce the very masculinizing parts of the face to
37:54
make the face appear more feminized.
37:57
The most studied anthropomorphically is
38:01
from various studies, that it's the middle third of the glabellar
38:05
prominence right between the eyebrows.
38:08
That frontal ridge tends to be very masculinizing, and so the main goal is often to
38:12
just reduce that, and patients
38:15
can have a much more feminized appearance.
38:17
So here's an example of someone who had undergone
38:20
facial feminization with frontal reduction, and you can see there are these various
38:23
angles that help the surgeon to achieve their operative goal or the
38:27
ideal reduction for that patient.
38:30
And you can see what the frontal sinuses may look like if they have to enter them
38:34
for that surgery. Here's an example of someone who did a frontal sinus setback.
38:38
Again, they may have
38:40
bone grafting material to close the sinus or osteosynthesis plates.
38:45
Here's an example where they thought there was infection in the frontal sinus and
38:48
in the
38:50
bone graft there, but it was just some basic sinusitis related
38:54
to the surgery.
38:56
Midface feminization, so augmentation of the cheeks and cheekbones.
38:59
This can be done with soft tissue fillers, as you see in both the CT and MRI
39:03
here. So if you see that incidentally, just understand that's probably what was
39:06
going on there. You can place implants.
39:09
There are malar implants or silicone implants that can be placed.
39:12
This middle image shows one where they thought there might've been an infection in
39:15
the left implant because it had lifted, and so it showed that it just
39:19
had come undone, and they needed to replace it.
39:23
We may do preoperative 3D printing with our CT data to
39:27
help guide custom implant formation and placement.
39:31
So, I know this is at lunch, so I apologize for the surgical image there,
39:34
but I'm just showing that you can do custom face implants, as in this one.
39:39
Lower face feminization, again, changing the angle of the jaw
39:43
and making it a more feminized approach, kind of a more pointy chin rather than
39:47
a squared-off masculine chin by various
39:50
means.
39:53
Excuse me. So what's the risk of stroke from hormones?
39:55
We talked about thromboembolic phenomenon.
39:57
There is a slightly increased risk of stroke among persons receiving estrogens.
40:02
And the highest risk, again, is those same oral ethinylestradiol, the
40:06
non-bioequivalent
40:08
estrogens, smoking, and other cardiovascular risk factors.
40:11
I have two examples of stroke in trans women.
40:15
Unfortunately, both were in the lateral medulla, as in this case.
40:18
But keep that in mind that these patients may be at high risk, especially if
40:21
they're not getting monitored or if they're super physiologic on their dosing, as
40:25
were both of the cases that I have. So again, this is all from that Kaiser study
40:29
as well, that they showed increased risk of stroke.
40:32
You may have hormone-responsive tumors.
40:34
Both prolactinomas and meningiomas are under the influence of hormones, and so you
40:38
may see these incidentally. And if they're growing, you might just reduce the
40:41
hormone dosing to help reduce the size of these tumors as
40:45
appropriate.
40:47
All right, next patient.
40:49
How am I doing on time? Getting along there.
40:52
So trans woman received feminizing hormones for six years, breast augmentation for
40:56
eight, or eight years prior with silicone injections.
41:00
Vaginoplasty two weeks prior and coming with pelvic pain and fever.
41:03
Mother and sister with breast cancer. She is a police officer.
41:08
So vaginoplasty
41:11
is the
41:14
creation of a functionally acceptable neovagina.
41:17
There are various ways to do this. The most widely studied and performed is the
41:21
penoscrotal inversion vaginoplasty, which is depicted in the upper image,
41:24
where there's blunt dissection of the retroprosthetic space.
41:27
The penile skin, I'll discuss here in a little bit, is inverted, and so they have a
41:31
skin-lined neovagina.
41:34
And then an option for usually revision is the intestinal interposition, which
41:38
can be a pedicled flap of small bowel or colon
41:42
to the perineum.
41:44
So with the penoscrotal inversion vaginoplasty, the penis is disassembled.
41:48
You can see the blue marks is where they make their incisions.
41:51
They will remove as much cavernous tissue as possible, so that's the erectile
41:55
tissue.
41:56
They preserve the penile skin shaft.
41:59
They do orchiectomy at this time. They will reduce the length of the urethra.
42:04
And then with the glans and dorsal neurovascular bundle,
42:08
here they will reduce the size of the glans to create the neoclitoris, and this
42:12
will remain intact sensate-wise, so patients can actually have sexual
42:16
satisfaction from this. And then they will
42:20
do urethplasty and bring it right underneath the clitoris there.
42:24
And you can see this tube from the skin-lined neovagina there.
42:28
And they'll use the scrotal skin to produce the neolabia.
42:32
So imaging wise, it can be difficult to assess this area on
42:36
CTs, as it's usually collapsed down.
42:38
Here's an example of some MRI where it's collapsed down.
42:41
Often patients have dilators after this surgery to keep the
42:45
patency of the neovagina, and so they'll have these dilator instruments.
42:47
So if you're specifically interpreting something
42:51
for
42:53
evaluation of the neovagina, you might ask them to bring their dilator instruments.
42:56
Just make sure there's no metal components in those.
42:59
Otherwise, you can do
43:01
water sensitive gel material to look for fistulas, for
43:05
example. These are some measurements postoperatively
43:09
that have been compared to cisgender women
43:11
to basically measure how close are we achieving
43:16
anatomical results with what would be expected for cis women.
43:19
And these
43:20
have implications for sexual satisfaction and function of the neovagina after
43:24
surgery. So surgeons may request these, and this available in this
43:27
article. Complications, as you would expect, early
43:31
post-op complications with hemorrhage and infection are kind of the ones that you
43:35
worry about first. And then kind of
43:40
longer term ones, including vaginal stenosis,
43:43
rectovaginal fistula example. Here's an example of just
43:47
several pelvic abscesses after surgery.
43:50
And again, it's highly variable. This is one on T2 MRI where you have
43:54
residual T2 of high signal, and that's all the erectile tissue that's left
43:57
behind. So with sexual stimulation, that can engorge and be
44:01
uncomfortable for patients. And it can also be a source of hemorrhage.
44:05
This patient had a Mons abscess, and when they do the
44:10
glans positioning for the neoclitoris, they place that dorsal neurovascular
44:14
bundle up here. So you can imagine how painful this must've been for the patient,
44:18
who unfortunately also developed a fistula to her neovagina.
44:24
So here's enhancing residual tissue.
44:26
You can see there's just a little bit here on the left image.
44:29
Whereas on the right, there's much more cavernous tissue that was left behind.
44:34
Here's an example of a retro neovaginal fistula with
44:38
barium enema, so abnormal connection with the neovagina seen here, and
44:42
then they later scan the patient with CT, and it helps the surgeons to
44:45
delineate that defect and plan their surgery.
44:50
Chronic complication can be neovaginal prolapse or
44:54
there's a lot of work done in the pelvic floor.
44:57
So pelvic floor weakening can lead to this prolapse.
44:59
And this was a dynamic MRI that showed that it was a fixed defect and quite large,
45:03
so it had to be repaired.
45:06
All right. Final patient here is Andrew, a trans man, presented with groin
45:09
pain and cold penis after a 12-hour car ride.
45:13
He had received testosterone injections monthly.
45:15
He had had chest masculinization, phalloplasty, and scrotoplasty two years prior,
45:19
and he's a professional snowboarder.
45:22
So
45:26
phalloplasty is creation of a neophallus, and
45:30
whether it's from a phalloplasty techniques or you can do metoidioplasty as another
45:33
option. The most widely studied is this radial forearm free flap, where a
45:38
donor tissue site from the dorsal forearm is brought down
45:42
and anastomosed to the groin. And so they'll take with them
45:46
the neurovascular structures of the skin.
45:50
They'll do skin grafting to close that donor site.
45:53
But they will roll that skin donor flap into a
45:57
tube-in-tube configuration. So it's a skin-lined neourethra.
46:01
And then it's got some level of bulk to it.
46:03
So they will then reanastomose the vessels,
46:07
usually with the inferior epigastric arteries down in the groin.
46:11
And then they will also do microsurgery to reanastomose the nerve endings,
46:15
so you can actually have a tactile and sensile neophallus.
46:19
You can also do just a pedicle flap from the thigh, and so that's one option.
46:23
And you may see those changes on a CT where the donor
46:26
site looks altogether different than the contralateral thigh.
46:31
Metoidioplasty is a little different, actually has fewer complications
46:36
than the other surgery, but basically a neophallus is created from
46:40
hormonally hypertrophied clitoris.
46:41
So under the influence of testosterone, the clitoris will hypertrophy and
46:45
grow. And some up to six centimeters have been
46:49
reported. So they'll take advantage of that fact
46:52
and go ahead and perform this surgery.
46:56
The downsides is often patients can't get as much length as the other phalloplasty
47:00
procedures. But sometimes this is all the patient really needs, but it does allow
47:03
them
47:05
to have upright micturition and natural erections.
47:08
And it's a much less complicated surgery.
47:12
Here's an example of that, a hypertrophied clitoris here, and then you can see
47:15
the homologous erectile tissue is maintained so they can actually achieve
47:19
erections.
47:21
And then, let's see. You may do a CTA if you're
47:25
planning for contralateral thigh phalloplasty for looking at the
47:29
graft or the potential graft or donor site.
47:34
Post-op,
47:35
the urethrogram is going to be the gold standard for evaluating their urethra.
47:39
Again, most complications are related to their urethra or the blood supply to
47:42
these phalloplasties. And so,
47:45
there's the pendulous or the phalloplasty urethra that's been created and brought
47:49
down as we showed. Then there's this mid portion, usually from buccal
47:53
or vaginal skin grafting, that they will connect that to the native urethra
47:57
posteriorly. So you can see that these sites where there's
48:00
tenuous blood supply is where we tend to have the complications.
48:05
And again, here's an example of one where you have stenosis at this
48:08
juncture that led to dehiscence and leak
48:12
posteriorly. So, they're getting retrograde urethrograms frequently.
48:16
There's some great publications on this, in the expected imaging of it
48:21
In this case, it was just a simple growing hematoma, but they were worried about
48:24
the patency of the supplying artery.
48:27
So you can see that it was patent on this CTA.
48:31
Back to our patient. So he showed up with a cold penis.
48:34
A long car ride, and they did a Doppler ultrasound showing that the anastomotic
48:37
artery is thrombosed. They tried to clear it with
48:41
interventional radiology, unfortunately not soon enough, as he developed
48:45
necrosis in the distance from that ischemic event.
48:50
Some patients elect to get implants and erectile devices.
48:53
They look just like any other erectile implant device that we might see with
48:56
cisgender men. Differences, they may have complications more frequently
49:00
because it doesn't have a fibrous tunica to sit in.
49:04
It's in that phalloplasty tissue, which may be more at
49:08
risk for
49:10
rupture and breakdown.
49:13
Here's one example that's unfortunately, the patient developed infection around all
49:16
of the erectile implant
49:19
device components, and so this is all abscess, and it needed to be removed.
49:23
They allowed the infection to cool down before they did a revision.
49:28
So looking globally at how we improve this approach.
49:32
One is all the things I mentioned and the ways that we can improve our
49:36
approach to the patients in the department.
49:38
So they're listed here, but keep in mind, this patient population may
49:42
require a little more effort or emphasis on gender
49:46
identification and pronoun use.
49:52
Always remember that these can be invasive exams, they can be traumatic exams, as
49:55
we showed,
49:56
and so allow the patient to have autonomy at the site of the imaging.
50:02
Excuse me.
50:04
If your department cares for these patients, make sure that patients know
50:08
about it. This is an example where they studied all the breast imaging facilities
50:12
in the United States and showed that overall, many were not ready.
50:16
And this is an older publication, but I'm sure that's improved since then.
50:19
But many were not ready to provide adequate care for transgender folks.
50:24
Here's one where they looked at Google webpages and website searches
50:27
for radiology departments and transgender
50:31
experts or care there. And even in high volume centers like in
50:35
New York and San Francisco, there was no mention of transgender care in these
50:38
radiology department websites at this time.
50:42
I encourage a multidisciplinary approach.
50:44
Work with your referring clinicians, work with patients,
50:48
to ensure that the radiology department is ready to receive these patients in a
50:52
meaningful and supportive way.
50:55
Again, I always encourage community feedback, so make sure you're having
50:59
patients as part of this discussion so that you can really tailor it to the needs
51:02
of the community.
51:05
We have a multidisciplinary transgender health clinic here.
51:08
I sit on that panel from a radiology perspective, so I'm in the
51:12
background on Zoom in this image, but we do have multidisciplinary care.
51:16
But include yourself in those populations.
51:18
So reach out to your trans health center if you have one,
51:21
and ask if you can be part of that team.
51:23
And I think you'll find that everyone's very welcome to having a radiologist
51:27
to support them.
51:30
Excuse me.
51:33
Again, most importantly, listen to the community, listen to the patients.
51:35
These are more quotes from our survey.
51:38
They'll tell you where we could improve or where we're doing well.
51:42
So keep that in mind.
51:45
At this point, I will conclude and take any questions.
51:52
Thank you so much for this presentation, Dr Stoll. That was great.
51:56
We will open the floor for some questions, and we've got a couple in the Q&A box.
51:59
I don't know if you're able to see that on your Zoom.
52:02
If not, I can read
52:06
them.
52:09
Let's see.
52:11
Should be a quote bubble with a question mark in it.
52:14
I see a webinar chat.
52:17
Not that one.
52:20
Do you have a more
52:22
option?
52:23
Got it.
52:23
Awesome.
52:24
All right. So
52:29
excuse my coughing. I developed laryngitis over the weekend.
52:31
So how do we report about uterus, ovaries, prostate, and
52:35
seminal vesicles in ultrasound or CT if they are visualized in someone who's
52:38
transgender?
52:41
So the question to me seems like how to be sensitive to very
52:45
gendered anatomy related to what the
52:48
patient may see in their reports, if that's correct.
52:53
That's a question that comes up frequently.
52:56
What I have always encouraged and what I think in general the consensus
53:00
is among experts is be objective, say what you're
53:03
seeing,
53:05
because it's still the anatomy, right?
53:07
Often, these patients know what tissue they have, right?
53:10
And
53:11
certain individuals may be more dysphoric about discussing it or seeing it
53:14
reported.
53:16
But I think as long as you're not leaning on gender, like using male, female,
53:20
and really just reporting objectively, this is prostate tissue.
53:24
We have to stay objective, right?
53:28
And so that's one way. Another option is if
53:32
there is a patient that's very sensitive to that and doesn't want that sort of
53:35
information in their report,
53:38
there are ways to describe around it.
53:40
You can issue patient-friendly reports and then the separate report
53:44
for the clinician, for example. It takes that
53:48
crosstalk to understand ahead of time
53:51
how we can do things.
53:54
One thing that I tend to do is if I think someone's going to be sensitive to the
53:58
report information,
53:59
for example, on a CT abdomen and pelvis, I'll often say,
54:03
"No pelvic mass," and just avoid the mention of a
54:07
uterus and ovaries, but I'll still obviously evaluate it.
54:11
That's one way, but again,
54:13
there are different ways you can do it, and it's going to be patient specific.
54:16
Overall, I've found that most patients are totally understanding of the anatomy
54:20
that they have. Often, they don't want it anymore, and so they're often
54:24
coming to see us to get rid of it, right?
54:26
So-
54:27
And so I think just be objective, and that's the tissue that you see, right?
54:32
That's probably the best approach.
54:37
Can I go over the anatomy and point out the pelvic floor defect?
54:42
Excuse me.
54:43
I did show two sagittal images, one on CT, one on dynamic
54:47
MRI. Again, the
54:50
blunt dissection goes in the retroprostatic space through the peritenium,
54:54
and this was a chronic defect where the patient had fullness.
54:58
I only have those two images to show, so I can't scroll and really go through the
55:01
detail, but that space becomes weakened.
55:04
And that was an older
55:06
example, a case from several years ago.
55:09
And so since then, it's become the
55:13
standard of care to do
55:14
pelvic therapy with a pelvic therapist who specializes in pelvic floor
55:18
before surgery to really strengthen all those muscles to prevent this complication.
55:22
And then after the surgery, there's a lot of pelvic physiotherapy that's done
55:27
to strengthen that. So
55:28
we were able to do the dynamic MRI because that surgeon wanted to know, is this a
55:32
fixed defect or does it slide at all?
55:35
And so that was the reason for that there.
55:37
I'm sorry I don't have more detailed images to provide there.
55:44
So when I say that MRI is more sensitive than CT
55:48
for postoperative complications,
55:51
it depends what you're looking for.
55:52
So abscess, of course, CT is going to be your modality of choice with
55:56
contrast.
55:58
For most things, CT can get it.
56:01
If you're specifically looking at the nature of the
56:05
neovagina,
56:07
for example, then I think MRI is going to be better, if
56:11
you're specifically looking for that.
56:13
And I showed you the measurements and things that surgeons might like to see.
56:17
But I would wait for the postoperative period to calm down, and then maybe
56:21
six months to a year and beyond, then you can start using the MRI,
56:25
as I mentioned. It's going to be indication specific, I
56:29
think, and you would use your judgment.
56:31
The references that I left in the
56:34
presentation outline and detail that a little more.
56:38
So I would encourage you to check those out as well.
56:45
Any other question?
56:48
I think you got them all.
56:50
Okay. All right. Well, thank you again for the discussion,
56:54
for your time. I'm open to any further questions down the
56:58
road. Please just reach out.
57:00
Thank you so much for this presentation. Really appreciate it.
57:03
Thank you.
57:03
And thank you for everyone for participating in today's noon conference.
57:06
We will email out a link to this replay later today.
57:11
Be sure to join us next week on August 13th at 12:00 PM Eastern, where Dr.
57:15
Parisa Kaviani will deliver a lecture entitled "AI-Generated Radiology
57:18
Impressions." You can register for that at medality.com, and follow us
57:22
on social media for updates on future noon conferences.
57:26
Thanks again for learning with us, and have a great day.